Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 22, 2018Journal for ImmunoTherapy of CancerOpen Access

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does avelumab improve objective response rate in patients with previously treated metastatic adrenocortical carcinoma?

Population

50 patients with previously treated metastatic adrenocortical carcinoma and prior platinum-based therapy

Design

Cohort

Follow-up

median 16.5 months

Authors

CTChristophe Le TourneauCHChristopher HoimesCZCorrine Zarwan

Discussion

Loading...

Member takes

Overview

Low response rate does not support routine use; leaves open avelumab's role in platinum-treated metastatic adrenocortical carcinoma.

Structured PICO

Does avelumab improve objective response rate in patients with previously treated metastatic adrenocortical carcinoma?

P
Population
50 patients with previously treated metastatic adrenocortical carcinoma (mACC) and prior platinum-based therapy
I
Intervention
Avelumab 10 mg/kg intravenously every 2 weeks (continuation of mitotane permitted)
O
Outcome
Objective response rate (ORR) assessed by RECIST v1.1 and safetysurrogate

Avelumab showed modest clinical activity (6% ORR) and a manageable safety profile in patients with platinum-treated metastatic adrenocortical carcinoma.

Cite This Study

Tourneau et al. (2018) studied this question.

synapsesocial.com/papers/6a810e1dada1eccddc338de7https://doi.org/10.1186/s40425-018-0424-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment2015 · 232 citations
  2. 2Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma2011 · 135 citations
  3. 3Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update2017 · 2,147 citations
  4. 4Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study2010 · 164 citations
  5. 5Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial2017 · 295 citations